Do analysts recommend BJDX or HSCS?

HeartSciences has a consensus target price of $8.00, indicating a potential upside of 53.85%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, BJDX or HSCS?

HeartSciences is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bluejay Diagnostics N/A N/A -$6.85M -$7.11 N/A HeartSciences N/A N/A -$9.14M -$3.22 N/A

Is BJDX or HSCS more profitable?

Bluejay Diagnostics' return on equity of -125.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets Bluejay Diagnostics N/A -125.00% -99.79% HeartSciences N/A -816.90% -181.97%

Does the media favor BJDX or HSCS?

In the previous week, HeartSciences had 12 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 13 mentions for HeartSciences and 1 mentions for Bluejay Diagnostics. HeartSciences' average media sentiment score of 0.29 beat Bluejay Diagnostics' score of -0.35 indicating that HeartSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bluejay Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral HeartSciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BJDX or ICU?

SeaStar Medical has a consensus target price of $8.00, indicating a potential upside of 125.99%. Given SeaStar Medical's stronger consensus rating and higher probable upside, analysts clearly believe SeaStar Medical is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SeaStar Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer BJDX or ICU?

In the previous week, Bluejay Diagnostics and Bluejay Diagnostics both had 1 articles in the media. SeaStar Medical's average media sentiment score of 0.00 beat Bluejay Diagnostics' score of -0.35 indicating that SeaStar Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bluejay Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SeaStar Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend TMDIF or BJDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TMDIF or BJDX more profitable?

Titan Medical's return on equity of -82.31% beat Bluejay Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Titan Medical N/A -82.31% -51.47% Bluejay Diagnostics N/A -125.00% -99.79%

Does the media refer more to NMTC or BJDX?

In the previous week, NeuroOne Medical Technologies and NeuroOne Medical Technologies both had 1 articles in the media. NeuroOne Medical Technologies' average media sentiment score of 0.33 beat Bluejay Diagnostics' score of -0.35 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroOne Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bluejay Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend IRIX or BJDX?

IRIDEX currently has a consensus price target of $3.00, suggesting a potential upside of 347.76%. Given IRIDEX's stronger consensus rating and higher possible upside, equities research analysts clearly believe IRIDEX is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IRIDEX 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Bluejay Diagnostics (BJDX) Competitors

$0.92 +0.08 (+8.88%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.95 +0.03 (+2.83%)

As of 09/18/2026 07:59 PM Eastern

Compare

BJDX vs. HSCS, ICU, TMDIF, NMTC, and IRIX

Should you buy Bluejay Diagnostics stock or one of its competitors? Bluejay Diagnostics's main competitors and comparable companies include HeartSciences (HSCS), SeaStar Medical (ICU), Titan Medical (TMDIF), NeuroOne Medical Technologies (NMTC), and IRIDEX (IRIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Bluejay Diagnostics compare to HeartSciences?

Bluejay Diagnostics (NASDAQ:BJDX) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Bluejay Diagnostics has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, HeartSciences has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

In the previous week, HeartSciences had 12 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 13 mentions for HeartSciences and 1 mentions for Bluejay Diagnostics. HeartSciences' average media sentiment score of 0.29 beat Bluejay Diagnostics' score of -0.35 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bluejay Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartSciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bluejay Diagnostics' return on equity of -125.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-125.00%	-99.79%
HeartSciences	N/A	-816.90%	-181.97%

HeartSciences has a consensus target price of $8.00, indicating a potential upside of 53.85%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 6.1% of Bluejay Diagnostics shares are held by insiders. Comparatively, 4.9% of HeartSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

HeartSciences is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A

Summary

HeartSciences beats Bluejay Diagnostics on 7 of the 13 factors compared between the two stocks.

How does Bluejay Diagnostics compare to SeaStar Medical?

Bluejay Diagnostics (NASDAQ:BJDX) and SeaStar Medical (NASDAQ:ICU) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

SeaStar Medical has a consensus target price of $8.00, indicating a potential upside of 125.99%. Given SeaStar Medical's stronger consensus rating and higher probable upside, analysts clearly believe SeaStar Medical is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bluejay Diagnostics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, SeaStar Medical has a beta of -1.05, meaning that its share price is 205% less volatile than the broader market.

Bluejay Diagnostics has higher earnings, but lower revenue than SeaStar Medical. SeaStar Medical is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A
SeaStar Medical	$1.23M	12.69	-$12.15M	-$3.91	N/A

18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are held by institutional investors. 6.1% of Bluejay Diagnostics shares are held by insiders. Comparatively, 0.7% of SeaStar Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Bluejay Diagnostics and Bluejay Diagnostics both had 1 articles in the media. SeaStar Medical's average media sentiment score of 0.00 beat Bluejay Diagnostics' score of -0.35 indicating that SeaStar Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bluejay Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
SeaStar Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bluejay Diagnostics has a net margin of 0.00% compared to SeaStar Medical's net margin of -795.51%. Bluejay Diagnostics' return on equity of -125.00% beat SeaStar Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-125.00%	-99.79%
SeaStar Medical	-795.51%	-162.75%	-109.89%

Summary

Bluejay Diagnostics beats SeaStar Medical on 8 of the 14 factors compared between the two stocks.

How does Bluejay Diagnostics compare to Titan Medical?

Titan Medical (NASDAQ:TMDIF) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

0.0% of Titan Medical shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by company insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Bluejay Diagnostics had 1 more articles in the media than Titan Medical. MarketBeat recorded 1 mentions for Bluejay Diagnostics and 0 mentions for Titan Medical. Titan Medical's average media sentiment score of 0.00 beat Bluejay Diagnostics' score of -0.35 indicating that Titan Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Titan Medical	Neutral
Bluejay Diagnostics	Neutral

Titan Medical's return on equity of -82.31% beat Bluejay Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
Bluejay Diagnostics	N/A	-125.00%	-99.79%

Titan Medical has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Titan Medical has higher revenue and earnings than Bluejay Diagnostics. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.74	$6.95M	$0.05	2.30
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Titan Medical beats Bluejay Diagnostics on 8 of the 12 factors compared between the two stocks.

How does Bluejay Diagnostics compare to NeuroOne Medical Technologies?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 11.8% of NeuroOne Medical Technologies shares are held by insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, NeuroOne Medical Technologies and NeuroOne Medical Technologies both had 1 articles in the media. NeuroOne Medical Technologies' average media sentiment score of 0.33 beat Bluejay Diagnostics' score of -0.35 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bluejay Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroOne Medical Technologies has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

NeuroOne Medical Technologies currently has a consensus target price of $7.33, indicating a potential upside of 427.58%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, equities research analysts plainly believe NeuroOne Medical Technologies is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bluejay Diagnostics has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -71.50%. Bluejay Diagnostics' return on equity of -125.00% beat NeuroOne Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%
Bluejay Diagnostics	N/A	-125.00%	-99.79%

NeuroOne Medical Technologies has higher revenue and earnings than Bluejay Diagnostics. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10M	1.05	-$3.61M	-$0.95	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A

Summary

NeuroOne Medical Technologies beats Bluejay Diagnostics on 9 of the 14 factors compared between the two stocks.

How does Bluejay Diagnostics compare to IRIDEX?

IRIDEX (NASDAQ:IRIX) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

IRIDEX has higher revenue and earnings than Bluejay Diagnostics. IRIDEX is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IRIDEX	$52.67M	0.22	-$4.44M	-$0.20	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A

In the previous week, Bluejay Diagnostics had 1 more articles in the media than IRIDEX. MarketBeat recorded 1 mentions for Bluejay Diagnostics and 0 mentions for IRIDEX. IRIDEX's average media sentiment score of 0.21 beat Bluejay Diagnostics' score of -0.35 indicating that IRIDEX is being referred to more favorably in the media.

Company	Overall Sentiment
IRIDEX	Neutral
Bluejay Diagnostics	Neutral

IRIDEX currently has a consensus price target of $3.00, suggesting a potential upside of 347.76%. Given IRIDEX's stronger consensus rating and higher possible upside, equities research analysts clearly believe IRIDEX is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bluejay Diagnostics has a net margin of 0.00% compared to IRIDEX's net margin of -6.88%. IRIDEX's return on equity of 0.00% beat Bluejay Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IRIDEX	-6.88%	N/A	-12.55%
Bluejay Diagnostics	N/A	-125.00%	-99.79%

IRIDEX has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

20.1% of IRIDEX shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 8.6% of IRIDEX shares are owned by company insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

IRIDEX beats Bluejay Diagnostics on 11 of the 15 factors compared between the two stocks.

Get Bluejay Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BJDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BJDX vs. The Competition

Export

Metric	Bluejay Diagnostics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.11M	$5.55B	$7.24B	$13.19B
Dividend Yield	N/A	1.80%	2.57%	12.81%
P/E Ratio	-0.13	25.34	275.49	25.40
Price / Sales	N/A	72.49	646.01	89.45
Price / Cash	N/A	32.64	76.25	51.42
Price / Book	0.11	5.69	10.46	6.33
Net Income	-$6.85M	$151.55M	$3.49B	$358.33M
7 Day Performance	2.53%	0.66%	0.59%	1.12%
1 Month Performance	-2.13%	-3.33%	-1.74%	-2.39%
1 Year Performance	-84.25%	6.79%	18.13%	5.35%

Bluejay Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BJDX Bluejay Diagnostics	0.8587 of 5 stars	$0.92 +8.9%	N/A	-84.2%	$4.11M	N/A	N/A	6
HSCS HeartSciences	2.2675 of 5 stars	$3.76 +9.4%	$8.00 +112.5%	+49.0%	$14.58M	N/A	N/A	10	Trending News Earnings Report Analyst Upgrade Analyst Revision
ICU SeaStar Medical	2.7784 of 5 stars	$3.06 +1.2%	$8.00 +161.9%	-60.7%	$13.47M	$1.23M	N/A	2	News Coverage Analyst Upgrade
TMDIF Titan Medical	N/A	$0.11 -5.2%	N/A	-68.5%	$13.01M	$17.63M	N/A	50	Gap Up
NMTC NeuroOne Medical Technologies	3.1629 of 5 stars	$1.44 -1.5%	$7.33 +410.0%	-75.1%	$12.99M	$12.10M	N/A	20	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BJDX) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bluejay Diagnostics (BJDX) Competitors

BJDX vs. HSCS, ICU, TMDIF, NMTC, and IRIX

How does Bluejay Diagnostics compare to HeartSciences?

Summary

How does Bluejay Diagnostics compare to SeaStar Medical?

Summary

How does Bluejay Diagnostics compare to Titan Medical?

Summary

How does Bluejay Diagnostics compare to NeuroOne Medical Technologies?

Summary

How does Bluejay Diagnostics compare to IRIDEX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BJDX vs. The Competition

Bluejay Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bluejay Diagnostics (BJDX) Competitors

BJDX vs. HSCS, ICU, TMDIF, NMTC, and IRIX

How does Bluejay Diagnostics compare to HeartSciences?

Which has more volatility and risk, BJDX or HSCS?

Does the media favor BJDX or HSCS?

Is BJDX or HSCS more profitable?

Do analysts recommend BJDX or HSCS?

Do insiders & institutionals believe in BJDX or HSCS?

Which has preferable valuation and earnings, BJDX or HSCS?

Summary

How does Bluejay Diagnostics compare to SeaStar Medical?

Do analysts recommend BJDX or ICU?

Which has more risk & volatility, BJDX or ICU?

Which has preferable valuation and earnings, BJDX or ICU?

Do insiders and institutionals believe in BJDX or ICU?

Does the media prefer BJDX or ICU?

Is BJDX or ICU more profitable?

Summary

How does Bluejay Diagnostics compare to Titan Medical?

Do insiders & institutionals hold more shares of TMDIF or BJDX?

Does the media refer more to TMDIF or BJDX?

Is TMDIF or BJDX more profitable?

Which has more risk and volatility, TMDIF or BJDX?

Which has higher earnings & valuation, TMDIF or BJDX?

Do analysts recommend TMDIF or BJDX?

Summary

How does Bluejay Diagnostics compare to NeuroOne Medical Technologies?

Do insiders & institutionals believe in NMTC or BJDX?

Does the media refer more to NMTC or BJDX?

Which has more risk and volatility, NMTC or BJDX?

Do analysts prefer NMTC or BJDX?

Is NMTC or BJDX more profitable?

Which has better valuation & earnings, NMTC or BJDX?

Summary

How does Bluejay Diagnostics compare to IRIDEX?

Which has higher earnings and valuation, IRIX or BJDX?

Does the media refer more to IRIX or BJDX?

Do analysts recommend IRIX or BJDX?

Is IRIX or BJDX more profitable?

Which has more risk and volatility, IRIX or BJDX?

Do insiders and institutionals hold more shares of IRIX or BJDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BJDX vs. The Competition

Bluejay Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools